LABORIE has completed its acquisition of Medical Measurement Systems (“MMS”). MMS is headquartered in Enschede, The Netherlands with a German subsidiary in Bottrop and US operations in Dover, New Hampshire. MMS is a global market leader in Gastrointestinal Diagnostics and Urodynamics.
LABORIE’s acquisition of MMS extends its Gastroenterology product offering following its acquisition of Unisensor in October 2014. Additionally, MMS’ Urodynamic product lines complement LABORIE’s Urodynamic product offering and extend its global reach.
“This is a very strategic acquisition for LABORIE,” stated Brian Ellacott, LABORIE President and CEO. “MMS has developed user-friendly products based on a unique platform that simultaneously supports Urology and Gastroenterology customers. We see tremendous opportunities to leverage this single platform across all our products and extend our global reach through the MMS global distribution network. We see this as a very complementary acquisition.”
MMS President, Arjen de Weerd stated, “We are very pleased to be part of the LABORIE team. The combined resources of these two innovative companies, will allow us to develop the “next generation” products our customers are requesting and expand our footprint globally. Both I and co-founder Jan-Willem van der Wal are eager to participate with the LABORIE team in building truly innovative products for the GI and Urology markets.”
LABORIE (www.laborie.com), headquartered in Toronto, Canada, is a leading global developer, manufacturer and marketer of innovative medical technology and consumables for the diagnosis and treatment of Urinary and Fecal Incontinence, as well as other pelvic floor disorders in the Urology, Gynecology, and Colorectal fields.
LABORIE Medical Technologies, a leading diagnostic and therapeutic medical technology company, today announced it has completed its acquisition of Clinical Innovations for an enterprise value of $525 million.
LABORIE Medical Technologies, a leading global developer and manufacturer of medical diagnostics and devices in the pelvic health and gastroenterology market, today announces the execution of a definitive agreement to acquire Clinical Innovations for an enterprise value of $525 million.
LABORIE Medical Technologies (“LABORIE”) and Cogentix Medical, Inc. (NASDAQ: CGNT) (“Cogentix”) today announced the completion of the acquisition by LABORIE of Cogentix through LABORIE’S affiliate Camden Merger Sub, Inc. (“Merger Sub”), a wholly owned subsidiary of LM US Parent, Inc. (“Parent”).